Latest news
FHTX: Precision oncology pipeline and Lilly partnership drive growth in chromatin-targeted therapeutics - TradingViewTradingView · Thu, 06 Aug 2026 14:39:44 GMTFoghorn Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 14:20:38 GMTFHTX: Reduced net loss, robust pipeline progress, and strong cash position support growth into 2028 - TradingViewTradingView · Thu, 06 Aug 2026 11:13:51 GMTFoghorn Therapeutics Inc. 2026: Revenue $16.07M, EPS ($0.1) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 11:11:00 GMTFHTX: Q2 2026 revenue surged on a $14.2M catch-up, narrowing net loss to $7.2M; cash runway remains solid - TradingViewTradingView · Thu, 06 Aug 2026 11:03:51 GMTFHTX Q2'26 Earnings: revenue estimate is 6.81M USD - TradingViewTradingView · Tue, 04 Aug 2026 11:00:14 GMTFoghorn Therapeutics Inc. Revenue Breakdown – NASDAQ:FHTX - TradingViewTradingView · Fri, 31 Jul 2026 22:06:39 GMTPrice to earnings forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingViewTradingView · Thu, 30 Jul 2026 05:59:46 GMT